

# CITATION REPORT

List of articles citing

**A case of recurrent bilateral uveitis independently associated with dabrafenib and pembrolizumab therapy**

**DOI: 10.1016/j.ajoc.2016.04.004**

**American Journal of Ophthalmology Case Reports, 2016, 2, 23-25.**

**Source:** <https://exaly.com/paper-pdf/64153836/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
27	CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects. <i>Retina</i> , <b>2018</b> , 38, 1063-1078	3.6	164
26	Drug-induced uveitis. <i>Current Opinion in Ophthalmology</i> , <b>2018</b> , 29, 588-603	5.1	39
25	Neoplasia and intraocular inflammation: From masquerade syndromes to immunotherapy-induced uveitis. <i>Progress in Retinal and Eye Research</i> , <b>2019</b> , 72, 100761	20.5	18
24	Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy. <i>American Journal of Ophthalmology</i> , <b>2019</b> , 202, 109-117	4.9	42
23	Management of Chronic Hypotony Following Bilateral Uveitis in a Patient Treated with Pembrolizumab for Cutaneous Metastatic Melanoma. <i>Ocular Immunology and Inflammation</i> , <b>2019</b> , 27, 1012-1015	2.8	7
22	Uveitis in Patients Treated with CTLA-4 and PD-1 Checkpoint Blockade Inhibition. <i>Ocular Immunology and Inflammation</i> , <b>2020</b> , 28, 217-227	2.8	32
21	A Case of Melanoma-Associated Retinopathy, Uveitis, and Optic Neuritis Associated With Pembrolizumab, Managed With Topical, Intravitreal, and Intravenous Steroids. <i>Journal of Vitreoretinal Diseases</i> , <b>2020</b> , 4, 220-226	0.7	1
20	Risk of non-infectious uveitis or myasthenia gravis in patients on checkpoint inhibitors in a large healthcare claims database. <i>British Journal of Ophthalmology</i> , <b>2020</b> ,	5.5	3
19	Ocular Complications of Checkpoint Inhibitors and Immunotherapeutic Agents: A Case Series. <i>Ocular Immunology and Inflammation</i> , <b>2020</b> , 1-6	2.8	7
18	"Giant cell arteritis manifesting as retinal arterial occlusion and paracentral acute middle maculopathy in a patient on pembrolizumab for metastatic uveal melanoma". <i>American Journal of Ophthalmology Case Reports</i> , <b>2020</b> , 20, 100891	1.3	4
17	Vogt-Koyanagi-Harada-like syndrome induced by immune checkpoint inhibitors in a patient with melanoma. <i>Clinical and Experimental Dermatology</i> , <b>2020</b> , 45, 908-911	1.8	4
16	Factors associated with ocular adverse event after immune checkpoint inhibitor treatment. <i>Cancer Immunology, Immunotherapy</i> , <b>2020</b> , 69, 2441-2452	7.4	5
15	BILATERAL CHOROIDAL DETACHMENTS SECONDARY TO IPILIMUMAB AND PEMBROLIZUMAB USE. <i>Retinal Cases and Brief Reports</i> , <b>2021</b> , 15, 230-233	1.1	2
14	Ocular Toxicity of Targeted Anticancer Agents. <i>Drugs</i> , <b>2021</b> , 81, 771-823	12.1	5
13	Retinal toxicities of systemic anticancer drugs. <i>Survey of Ophthalmology</i> , <b>2021</b> ,	6.1	1
12	Chronic Unilateral Uveitis with Macular Edema Secondary to Dabrafenib for Pilocytic Astrocytoma. <i>Case Reports in Ophthalmology</i> , <b>2021</b> , 12, 574-577	0.7	1
11	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. <b>2021</b> , 9,		58

10	Pharmacologically induced uveitis. <i>Survey of Ophthalmology</i> , <b>2021</b> , 66, 781-801	6.1	4
9	Immune checkpoint inhibitor associated ocular hypertension (from presumed trabeculitis). <i>American Journal of Ophthalmology Case Reports</i> , <b>2021</b> , 23, 101125	1.3	0
8	Ocular side effects of checkpoint inhibitors. <i>Survey of Ophthalmology</i> , <b>2021</b> , 66, 951-959	6.1	4
7	Bilateral panuveitis as a complication of systemic treatment of melanoma. <i>Medicina Clínica</i> , <b>2021</b> ,	1	
6	Noninfectious Anterior Uveitis. <i>Current Practices in Ophthalmology</i> , <b>2020</b> , 1-16	0	
5	Uveitis associated with cancer immunotherapy: long-term outcomes. <i>Immunotherapy</i> , <b>2021</b> , 13, 1465-1481	1.8	0
4	Bilateral panuveitis as a complication of systemic treatment of melanoma. <i>Medicina Clínica (English Edition)</i> , <b>2022</b> , 158, 445-445	0.3	0
3	Cancer Immunotherapy and Uveitis: Balancing Anti-Tumor Immunity and Ocular Autoimmunity. <i>International Ophthalmology Clinics</i> , <b>2022</b> , 62, 49-63	1.7	1
2	Ocular Inflammation Induced by Immune Checkpoint Inhibitors. <b>2022</b> , 11, 4993		1
1	Ocular adverse events associated with immune checkpoint inhibitors, a scoping review. <b>2023</b> , 13,		0